Roivant Sciences Ltd. $ROIV Shares Purchased by HighTower Advisors LLC

HighTower Advisors LLC boosted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 36.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,932 shares of the company’s stock after acquiring an additional 3,719 shares during the quarter. HighTower Advisors LLC’s holdings in Roivant Sciences were worth $141,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Patient Square Capital LP increased its position in Roivant Sciences by 2.1% in the 4th quarter. Patient Square Capital LP now owns 12,480,000 shares of the company’s stock valued at $147,638,000 after acquiring an additional 251,535 shares during the period. Invesco Ltd. increased its position in Roivant Sciences by 3.8% in the 1st quarter. Invesco Ltd. now owns 9,880,526 shares of the company’s stock valued at $99,695,000 after acquiring an additional 365,468 shares during the period. Bank of New York Mellon Corp increased its position in Roivant Sciences by 16.3% in the 1st quarter. Bank of New York Mellon Corp now owns 4,000,181 shares of the company’s stock valued at $40,362,000 after acquiring an additional 560,641 shares during the period. Northern Trust Corp increased its position in Roivant Sciences by 23.3% in the 4th quarter. Northern Trust Corp now owns 3,448,082 shares of the company’s stock valued at $40,791,000 after acquiring an additional 652,615 shares during the period. Finally, Nuveen LLC acquired a new stake in Roivant Sciences in the 1st quarter valued at approximately $31,988,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Stock Down 0.2%

Shares of NASDAQ:ROIV opened at $12.57 on Friday. The company’s fifty day moving average is $11.55 and its two-hundred day moving average is $11.01. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $13.08. The company has a market cap of $8.58 billion, a P/E ratio of -17.96 and a beta of 1.15.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 577,007 shares of the business’s stock in a transaction on Friday, June 20th. The shares were sold at an average price of $11.46, for a total transaction of $6,612,500.22. Following the sale, the insider directly owned 37,284,108 shares of the company’s stock, valued at $427,275,877.68. The trade was a 1.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Eric Venker sold 100,000 shares of the business’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $11.72, for a total transaction of $1,172,000.00. Following the sale, the chief executive officer directly owned 1,653,585 shares in the company, valued at approximately $19,380,016.20. This trade represents a 5.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,442,273 shares of company stock worth $16,553,796. Company insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. The Goldman Sachs Group upgraded Roivant Sciences to a “strong-buy” rating and set a $19.00 target price on the stock in a research report on Thursday, July 10th. Citigroup started coverage on Roivant Sciences in a research note on Tuesday. They set a “buy” rating and a $16.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, June 18th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $16.38.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.